Restless leg syndrome and risk of all-cause dementia: a nationwide retrospective cohort study

Table 4 Effect of dopamine agonist on the development of dementia in patients with RLS

	All-cause dementia cases (n (%))	Crude HR (95% CI)	p-value	aHR^a (95% CI)	p-value
Patients with RLS with dopamine agonist use^b	190 (9.8)	0.97 (0.74–1.28)	0.845	1.00 (0.76–1.32)	0.983
Patients with RLS without dopamine agonist use^b	70 (12.5)	1 (reference)		1 (reference)

Abbreviations: aHR, adjusted hazard ratio; CI, confidence interval; HR, hazard ratio; RLS, restless leg syndrome
^aAdjusted for age, sex, income, region, CCI score, history of sleep disorder, schizophrenia or other psychotic disorders, mood disorder, anxiety disorder, Parkinson’s disease, and iron deficiency anemia
^bDopamine agonists are pramipexole and ropinirole

ISSN: 1758-9193